Allosteric Modulation of Pathological Ataxin‐3 Aggregation: A Path to Spinocerebellar Ataxia Type‐3 Therapies

Spinocerebellar ataxia type 3 (SCA3) is a rare neurodegenerative disorder caused by the expansion of a polyglutamine (polyQ) repeat in ataxin-3 (Atx3) for which no disease-modifying therapies are available. The presence of protein inclusions enriched in polyQ-expanded Atx3 in neurons suggests that inhibiting its self-assembly may provide targeted therapies. Here, it is demonstrated that the supramolecular tweezer CLR01 binds to a lysine residue on a positively charged patch of the Atx3 catalytic Josephin domain, decreasing conformational fluctuations of the distal helical hairpin, without altering its ubiquitin hydrolase activity. This reduces exposure of the aggregation-prone region that initiates Atx3 self-assembly, ultimately delaying Atx3 amyloid fibril formation and reducing the secondary nucleation rate, a process linked to fibril proliferation and toxicity. CLR01's effects translate into the reversal of synapse loss in SCA3 cultured cortical neuron model, improve locomotor function in a Caenorhabditis elegans SCA3 model, and delay disease onset with reduced severity of motor symptoms in a SCA3 mouse model. These insights reveal a novel allosteric site for developing CLR01-inspired therapies targeting pathological aggregation while preserving essential functional sites. They also highlight that targeting allosteric sites in amyloid-forming proteins may provide new opportunities for safe therapeutic strategies for various protein misfolding disorders.

Authors

Institutions

Publication Details

Journal
Advanced Science
Published
2025-11-26
DOI
https://doi.org/10.1002/advs.202502216
Primary Topic
Genetic Neurodegenerative Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Allosteric Modulation of Pathological Ataxin‐3 Aggregation: A Path to Spinocerebellar Ataxia Type‐3 Therapies

Patrı́cia Maciel, Joseph A. Loo, Julio Vieyto‐Nuñez, Thomas Schräder et al.
Advanced Science
Genetic Neurodegenerative Diseases
article

Allosteric Modulation of Pathological Ataxin‐3 Aggregation: A Path to Spinocerebellar Ataxia Type‐3 Therapies

Patrı́cia Maciel, Joseph A. Loo, Julio Vieyto‐Nuñez, Thomas Schräder, Débora Serrenho, Joel Mieres‐Pérez, James W. Noble, Alexandra Silva, Daniela Vilasboas‐Campos, Sara Guerreiro, Andreia Teixeira‐Castro, Gal Bitan, Annalisa Pastore, Ana Luı́sa Carvalho, Niki Sepanj, Sandra Macedo‐Ribeiro, Daniela Monteiro‐Fernandes, Martyna Podlasiak, Elsa Sánchez‐García, Pedro M. Martins, Joana Pereira‐Sousa, Andreia Neves‐Carvalho, Francisco Figueiredo, Sara Duarte‐Silva, Carter Lantz, Joana S. Fraga, Beatriz Rodrigues, Frank‐Gerrit Klärner, Tatiana Van‐der‐Kellen
article en

Abstract

Spinocerebellar ataxia type 3 (SCA3) is a rare neurodegenerative disorder caused by the expansion of a polyglutamine (polyQ) repeat in ataxin-3 (Atx3) for which no disease-modifying therapies are available. The presence of protein inclusions enriched in polyQ-expanded Atx3 in neurons suggests that inhibiting its self-assembly may provide targeted therapies. Here, it is demonstrated that the supramolecular tweezer CLR01 binds to a lysine residue on a positively charged patch of the Atx3 catalytic Josephin domain, decreasing conformational fluctuations of the distal helical hairpin, without altering its ubiquitin hydrolase activity. This reduces exposure of the aggregation-prone region that initiates Atx3 self-assembly, ultimately delaying Atx3 amyloid fibril formation and reducing the secondary nucleation rate, a process linked to fibril proliferation and toxicity. CLR01's effects translate into the reversal of synapse loss in SCA3 cultured cortical neuron model, improve locomotor function in a Caenorhabditis elegans SCA3 model, and delay disease onset with reduced severity of motor symptoms in a SCA3 mouse model. These insights reveal a novel allosteric site for developing CLR01-inspired therapies targeting pathological aggregation while preserving essential functional sites. They also highlight that targeting allosteric sites in amyloid-forming proteins may provide new opportunities for safe therapeutic strategies for various protein misfolding disorders.

Advanced ScienceVol. 13(11)
California NanoSystems Institute (US), University of California, Los Angeles (US), King's College London (GB), TU Dortmund University (DE), Institut de Biologie Moléculaire et Cellulaire (FR), i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto (PT), University of Duisburg-Essen (DE), University of Coimbra (PT), University of Minho (PT)
National Ataxia Foundation, Amyloidosis Foundation, Deutsche Forschungsgemeinschaft, National Institutes of Health, Fundação para a Ciência e a Tecnologia
Openalex Percentile: Top 60%
Genetic Neurodegenerative Diseases
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.